INARI MEDICAL INC (NARI)
US45332Y1091 - Common Stock
Overall NARI gets a fundamental rating of 4 out of 10. We evaluated NARI against 193 industry peers in the Health Care Equipment & Supplies industry. While NARI has a great health rating, there are worries on its profitability. While showing a medium growth rate, NARI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NARI has reported negative net income.
NARI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NARI reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: NARI reported negative operating cash flow in multiple years.
1.2 Ratios
NARI's Return On Assets of -0.23% is fine compared to the rest of the industry. NARI outperforms 70.98% of its industry peers.
With a decent Return On Equity value of -0.34%, NARI is doing good in the industry, outperforming 71.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.23% | ||
| ROE | -0.34% | ||
| ROIC | N/A |
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NARI (88.03%) is better than 97.41% of its industry peers.
In the last couple of years the Gross Margin of NARI has grown nicely.
The Profit Margin and Operating Margin are not available for NARI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
2. Health
2.1 Basic Checks
NARI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NARI has been increased compared to 1 year ago.
NARI has more shares outstanding than it did 5 years ago.
NARI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.54 indicates that NARI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.54, NARI belongs to the top of the industry, outperforming 86.53% of the companies in the same industry.
NARI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.54 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
A Current Ratio of 3.09 indicates that NARI has no problem at all paying its short term obligations.
NARI has a Current ratio (3.09) which is comparable to the rest of the industry.
A Quick Ratio of 2.52 indicates that NARI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.52, NARI is in line with its industry, outperforming 51.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
NARI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.83%, which is quite impressive.
NARI shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.72%.
NARI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 135.60% yearly.
EPS 1Y (TTM)52.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-550%
Revenue 1Y (TTM)28.72%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Revenue growth Q2Q23.26%
3.2 Future
The Earnings Per Share is expected to grow by 138.95% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 13.42% on average over the next years. This is quite good.
EPS Next Y-1757.08%
EPS Next 2Y197.28%
EPS Next 3Y184.92%
EPS Next 5Y138.95%
Revenue Next Year19.25%
Revenue Next 2Y18.68%
Revenue Next 3Y18.17%
Revenue Next 5Y13.42%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NARI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 223.04, which means the current valuation is very expensive for NARI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NARI indicates a somewhat cheap valuation: NARI is cheaper than 65.80% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NARI to the average of the S&P500 Index (20.20), we can say NARI is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 223.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NARI indicates a somewhat cheap valuation: NARI is cheaper than 73.06% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 89.2 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NARI's earnings are expected to grow with 184.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y197.28%
EPS Next 3Y184.92%
5. Dividend
5.1 Amount
No dividends for NARI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INARI MEDICAL INC
NASDAQ:NARI (5/17/2024, 7:15:32 PM)
After market: 45.75 0 (0%)45.75
-0.55 (-1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.65B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 223.04 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.23% | ||
| ROE | -0.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.09 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)52.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1757.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)28.72%
Revenue growth 3Y52.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y